In Freiburg, the company manufactures essential components such as cytokines and growth factors used in these novel therapies. With an investment of more than EUR 140 million, Sartorius is reaffirming its strategic focus on this emerging business area, it states.

Related article

The European life science industry: The time to step up is now

Europe ranks highly when it comes to life science know-how and knowledge, but the region is falling behind when it comes to R&D and turning science into real-world solutions. Complex regulations, a fragmented market, scattered funding, and the potential US market tariffs are just some of the challenges ahead.

“Cell and gene therapies offer patients hope for curing diseases that were previously considered untreatable. Cytokines, growth factors, and cell culture media are essential for the development and manufacture of these innovative therapies. As a key site in our global network for these critical materials, Freiburg serves a dynamic market with high requirements for speed, scalability, and process reliability. By significantly expanding our capacities, we can respond much more flexibly to demand from our biopharma customers and support them even better in bringing cell and gene therapies to patients faster and more efficiently,” says René Fáber, Head of the Bioprocess Solutions Division and member of the Sartorius Executive Board.

The site covers approximately 18,000 square meters and can accommodate up to 180 employees.

In the Haid industrial park, state-of-the-art production, laboratory, and office spaces have been created. The site covers approximately 18,000 square meters and can accommodate up to 180 employees.

Related article

In focus: Development & manufacturing of mRNA

NLS asked Dr. Maya Fuerstenau-Sharp, Head of Marketing, Cell Culture Technologies, Bioprocess Solutions, at Sartorius about her experiences of mRNA development and manufacturing, and her view on the field and its potential.

The opening of the new plant marks an important milestone in the development of the Freiburg site. In 2021, Sartorius acquired a majority stake in CellGenix GmbH, which was founded in 1994 at the University Medical Center Freiburg. The company has been fully integrated into the Sartorius Group since early 2026. Over the past five years, the number of employees in Freiburg has nearly doubled to around 140 people.

The development of the site is part of a long-term investment program aimed at expanding Sartorius’s global research and manufacturing network.

The development of the site is part of a long-term investment program aimed at expanding Sartorius’s global research and manufacturing network. The objective is to prepare the company for further organic growth, strengthen its resilience, and continue to ensure high delivery reliability and consistent product quality across all locations.